title: A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
abstract: Exisulind is a sulfone derivative of sulindac that induces apoptosis and demonstrates synergy with docetaxel in lung cancer models. This study evaluated the safety, efficacy, and pharmacokinetic interactions of exisulind and docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer (NSCLC). Fifty-seven patients received 218 cycles of docetaxel (75 mg/m2) and carboplatin (area under the curve, 5.0) in combination with exisulind (125-250 mg orally twice daily). Two complete responses and 9 partial responses were observed among the 47 patients assessable for response (overall response rate, 23%). The median duration of response was 5.9 months and median survival was 9.4 months. The 1- and 2-year survival rates are 35% and 14%, respectively. The hematologic toxicities were consistent with those previously reported with docetaxel/carboplatin. The most common nonhematologic toxicities were mild to moderate fatigue, anorexia, nausea, and vomiting. The addition of exisulind to the chemotherapy regimen did not interfere with the metabolism or elimination of docetaxel and vice versa, and docetaxel did not interfere with the pharmacokinetic parameters of exisulind. This trial did not allow direct comparison of patients receiving docetaxel/carboplatin with and without exisulind, but when compared with historical data of docetaxel/carboplatin alone, the addition of exisulind does not appear to enhance antitumor activity, duration of response, or survival. Although preclinical data demonstrate increased apoptosis and prolonged survival for the combination of exisulind and docetaxel, multiple clinical trials do not support further clinical development of this combination regimen in patients with advanced NSCLC.
authors.affiliation: The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA. sjones@tnonc.com
authors.forename: Suzanne F
authors.initials: SF
authors.lastname: Jones
authors.forename: John G
authors.initials: JG
authors.lastname: Kuhn
authors.forename: F Anthony
authors.initials: FA
authors.lastname: Greco
authors.forename: Eric L
authors.initials: EL
authors.lastname: Raefsky
authors.forename: John D
authors.initials: JD
authors.lastname: Hainsworth
authors.forename: Natalie R
authors.initials: NR
authors.lastname: Dickson
authors.forename: Dana S
authors.initials: DS
authors.lastname: Thompson
authors.forename: Noel T
authors.initials: NT
authors.lastname: Willcutt
authors.forename: Melissa B
authors.initials: MB
authors.lastname: White
authors.forename: Howard A
authors.initials: HA
authors.lastname: Burris
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013467:Sulindac / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D043823:Taxoids / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D013467:Sulindac; D016190:Carboplatin; C025463:sulindac sulfone